(1 - 9 von 10
)
Investegate |Clavis Pharma ASA Announcements | Clavis Pharma ASA:...
www.investegate.co.uk
Investegate announcements from Clavis Pharma ASA, Clavis Pharmas NOK 129 million Private Placemen...
Drar inn 180 mill. på oljesalg | DN
www.dn.no
Midt i oljenedturen klarte fem oljegründere å selge en forretningsidé som gjør dem 180 millioner kroner rikere.
Advent Venture Partners' portfolio company Algeta raises NOK
www.adventls.com
Advent Life Sciences is one of Europe’s most established venture and growth capital firms, investing in world-class life sciences businesses. We seek out...
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway...
www.wallstreet-online.de
Geir Christian Melen, CEO of Clavis Pharma: ?We are at an exciting phase of development in Clavis Pharma. This new loan from Innovation ...
Clavis Pharma Receives US Orphan Drug Designation for ELACYT(TM)
www.bionity.com
... this orphan drug designation for ELACYT, in addition to the European Commission designation received last year" says Geir Christian Melen, ...
Clavis raises $20M after positive leukaemia trial | Science|Business
sciencebusiness.net
Geir Christian Melen, CEO of Clavis Pharma, said, “I am delighted we have been able to secure this additional funding from a wide range of ...
Clovis Negotiates Potentially $380M Deal to Develop Clavis Pharma’s...
www.genengnews.com
CP was developed using Lipid Vector Technology and is designed to allow gemcitabine to enter cancer cells without requiring uptake by the hENT1 nucleoside...
Norway’s Clavis signs $380 million deal with Clovis - PharmaTimes
www.pharmatimes.com
Norwegian drugmaker Clavis Pharma has signed a major licensing deal for its investigational anti-cancer drug with the USA’s Clovis Oncology. - News -...
Norway's Oncology Efforts Are Coalescing
www.genengnews.com
“We can improve existing drugs and have a specific technology for doing this,” explains Geir Christian Melen, CEO. Clavis' lead compound ...
sortiert nach Relevanz / Datum